↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Tyck till om SwePub Sök här!

Träfflista för sökning "WFRF:(Egyed T) "

Search: WFRF:(Egyed T)

Result 1-5 of 5

Sort/group result

Sort by: Hits per page:

Enumeration	Reference	Cover	Find
1.	Pinkney, T, et al. (author) The relationship between method of anastomosis and anastomotic failure after right hemicolectomy and ileo-caecal resection: an international snapshot audit 2017 In: Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland. - : Wiley. - 1463-1318 .- 1462-8910. ; 19:8, s. O296-O311 Journal article (peer-reviewed)
2.	Laszlo, T, et al. (author) Low-burden TP53 mutations represent frequent genetic events in CLL with an increased risk for treatment initiation 2024 In: The journal of pathology. Clinical research. - 2056-4538. ; 10:1, s. e351- Journal article (peer-reviewed)
3.	Bodor, C, et al. (author) Screening and monitoring of the BTKC481S mutation in a real-world cohort of patients with relapsed/refractory chronic lymphocytic leukaemia during ibrutinib therapy 2021 In: British journal of haematology. - : Wiley. - 1365-2141 .- 0007-1048. ; 194:2, s. 355-364 Journal article (peer-reviewed)
4.	Kotmayer, L, et al. (author) Landscape of BCL2 Resistance Mutations in a Real-World Cohort of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax 2023 In: International journal of molecular sciences. - : MDPI AG. - 1422-0067. ; 24:6 Journal article (peer-reviewed)abstract The oral, highly selective Bcl2 inhibitor venetoclax has substantially improved the therapeutic landscape of chronic lymphocytic leukemia (CLL). Despite the remarkable response rates in patients with relapsed/refractory (R/R) disease, acquired resistance is the leading cause of treatment failure, with somatic BCL2 mutations being the predominant genetic drivers underpinning venetoclax resistance. To assess the correlation between disease progression and the most common BCL2 mutations G101V and D103Y, sensitive (10−4) screening for the most common BCL2 mutations G101V and D103Y was performed in 67 R/R CLL patients during venetoclax single-agent or venetoclax–rituximab combination therapy. With a median follow-up time of 23 months, BCL2 G101V and D103Y were detected in 10.4% (7/67) and 11.9% (8/67) of the cases, respectively, with four patients harboring both resistance mutations. Ten out of eleven patients carrying BCL2 G101V and/or D103Y experienced relapse during the follow-up period, representing 43.5% of the cases (10/23) showing clinical signs of disease progression. All BCL2 G101V or D103Y variants were detected in patients receiving venetoclax as a continuous single-agent treatment while these mutations were not observed during or after fixed-duration venetoclax therapy. Targeted ultra-deep sequencing of BCL2 uncovered three additional variants in four patient samples obtained at relapse, suggesting convergent evolution and implying a cooperating role of BCL2 mutations in driving venetoclax resistance. This cohort is the largest R/R CLL patient population reported to date in which BCL2 resistance mutations were investigated. Our study demonstrates the feasibility and clinical value of sensitive screening for BCL2 resistance mutations in R/R CLL.
5.	Gango, A, et al. (author) Quantitative assessment of JAK2 V617F and CALR mutations in Philadelphia negative myeloproliferative neoplasms 2018 In: Leukemia research. - 1873-5835. ; 65, s. 42-48 Journal article (peer-reviewed)

Skapa referenser, mejla, bekava och länka

Permalink

Result 1-5 of 5

Refine your search

Type of publication: journal article (5)

Type of content: peer-reviewed (5)

Author/Editor: De Castro, S. (1); Meyer, J. (1); Rossi, E. (1); Sanchez, J. (1); Wang, X. (1); Lange, C. (1); show more...; Davies, E. (1); Pal, A. (1); Alonso, J. (1); Abraham-Nordling, M (1); Boyle, K (1); Fearnhead, N (1); Garcia-Granero, E (1); Golda, T (1); Hompes, R (1); Kapur, S (1); Kumar, S (1); Laurberg, S (1); Mikalauskas, S (1); Rocha, R (1); Vierimaa, M (1); Keller, M. (1); Martin, S. (1); Johnson, M. (1); Manca, G. (1); Williams, G. (1); Robertson, A. (1); Perry, R (1); Agarwal, T (1); Rasmussen, S (1); Evans, M. (1); Garcia, J. (1); Macdonald, E. (1); Patel, P. (1); Khan, A. (1); Hunt, L (1); Williams, M (1); Alam, N (1); Lozano, R (1); Pereira, J (1); Watson, A (1); Hussain, A (1); Morris, C (1); Evans, J. (1); Knops, S. (1); Sharma, A (1); Barker, J (1); Yamamoto, T. (1); Sartori, A. (1); Smirnov, A. (1); show less...

University: Karolinska Institutet (5); Uppsala University (1)

Language: English (5)

Year

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

Copyright © LIBRIS - National Library Systems
LIBRIS.kb.se

pil uppåt

Close

Copy and save the link in order to return to this view